Key precautions include monitoring for differentiation syndrome, QTc prolongation, and Guillain-Barré syndrome, with specific management protocols.

Critical Safety Monitoring and Drug Interactions

TIBSOVO requires vigilant monitoring for differentiation syndrome (fever, dyspnea, edema), managed with corticosteroids and hemodynamic support. QTc interval prolongation necessitates weekly ECGs and electrolyte correction; permanent discontinuation is mandated for life-threatening arrhythmias. Guillain-Barré syndrome warrants immediate drug cessation. Concomitant use of QTc-prolonging agents (e.g., fluoroquinolones) or strong CYP3A4 inducers (e.g., rifampin) should be avoided. Hepatic/renal impairment does not require dose adjustments unless severe (Child-Pugh C or eGFR <30 mL/min). Patients with pre-existing cardiac conditions require intensified ECG surveillance.